rs61754631

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_004484.4(GPC3):​c.1626A>G​(p.Ala542Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0103 in 1,201,163 control chromosomes in the GnomAD database, including 837 homozygotes. There are 3,145 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.053 ( 417 hom., 1428 hem., cov: 20)
Exomes 𝑓: 0.0060 ( 420 hom. 1717 hem. )

Consequence

GPC3
NM_004484.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:8

Conservation

PhyloP100: 0.239

Publications

4 publications found
Variant links:
Genes affected
GPC3 (HGNC:4451): (glypican 3) Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2009]
GPC3 Gene-Disease associations (from GenCC):
  • Simpson-Golabi-Behmel syndrome
    Inheritance: XL Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
  • Simpson-Golabi-Behmel syndrome type 1
    Inheritance: XL Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.92).
BP6
Variant X-133536241-T-C is Benign according to our data. Variant chrX-133536241-T-C is described in ClinVar as Benign. ClinVar VariationId is 137490.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.239 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.18 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GPC3NM_004484.4 linkc.1626A>G p.Ala542Ala synonymous_variant Exon 8 of 8 ENST00000370818.8 NP_004475.1 P51654-1Q53H15I6QTG3
GPC3NM_001164617.2 linkc.1695A>G p.Ala565Ala synonymous_variant Exon 9 of 9 NP_001158089.1 P51654-3Q53H15
GPC3NM_001164618.2 linkc.1578A>G p.Ala526Ala synonymous_variant Exon 8 of 8 NP_001158090.1 Q53H15B4DTD8
GPC3NM_001164619.2 linkc.1464A>G p.Ala488Ala synonymous_variant Exon 7 of 7 NP_001158091.1 P51654-2Q53H15

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GPC3ENST00000370818.8 linkc.1626A>G p.Ala542Ala synonymous_variant Exon 8 of 8 1 NM_004484.4 ENSP00000359854.3 P51654-1

Frequencies

GnomAD3 genomes
AF:
0.0530
AC:
5803
AN:
109415
Hom.:
415
Cov.:
20
show subpopulations
Gnomad AFR
AF:
0.184
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0198
Gnomad ASJ
AF:
0.00686
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000806
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00844
Gnomad NFE
AF:
0.000607
Gnomad OTH
AF:
0.0439
GnomAD2 exomes
AF:
0.0163
AC:
2981
AN:
182961
AF XY:
0.0103
show subpopulations
Gnomad AFR exome
AF:
0.200
Gnomad AMR exome
AF:
0.00831
Gnomad ASJ exome
AF:
0.00615
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000503
Gnomad OTH exome
AF:
0.00685
GnomAD4 exome
AF:
0.00601
AC:
6564
AN:
1091692
Hom.:
420
Cov.:
30
AF XY:
0.00481
AC XY:
1717
AN XY:
357228
show subpopulations
African (AFR)
AF:
0.197
AC:
5184
AN:
26260
American (AMR)
AF:
0.00991
AC:
349
AN:
35201
Ashkenazi Jewish (ASJ)
AF:
0.00672
AC:
130
AN:
19350
East Asian (EAS)
AF:
0.00
AC:
0
AN:
30183
South Asian (SAS)
AF:
0.000333
AC:
18
AN:
53996
European-Finnish (FIN)
AF:
0.0000247
AC:
1
AN:
40534
Middle Eastern (MID)
AF:
0.0121
AC:
50
AN:
4119
European-Non Finnish (NFE)
AF:
0.000255
AC:
213
AN:
836193
Other (OTH)
AF:
0.0135
AC:
619
AN:
45856
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.472
Heterozygous variant carriers
0
228
456
684
912
1140
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
160
320
480
640
800
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0532
AC:
5819
AN:
109471
Hom.:
417
Cov.:
20
AF XY:
0.0449
AC XY:
1428
AN XY:
31775
show subpopulations
African (AFR)
AF:
0.184
AC:
5500
AN:
29889
American (AMR)
AF:
0.0198
AC:
202
AN:
10198
Ashkenazi Jewish (ASJ)
AF:
0.00686
AC:
18
AN:
2622
East Asian (EAS)
AF:
0.00
AC:
0
AN:
3472
South Asian (SAS)
AF:
0.000808
AC:
2
AN:
2475
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
5690
Middle Eastern (MID)
AF:
0.00463
AC:
1
AN:
216
European-Non Finnish (NFE)
AF:
0.000607
AC:
32
AN:
52748
Other (OTH)
AF:
0.0433
AC:
64
AN:
1477
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
174
348
523
697
871
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
60
120
180
240
300
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0282
Hom.:
163
Bravo
AF:
0.0613
EpiCase
AF:
0.00104
EpiControl
AF:
0.000830

ClinVar

Significance: Benign
Submissions summary: Benign:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
Apr 11, 2014
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

May 05, 2016
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: The GPC3 variant, c.1626A>G (p.Ala542Ala) causes a synonymous change involving a non-conserved nucleotide with 5/5 in silico tools via Alamut predicting no significant effect on splicing, although these predictions have yet to be functionally assessed. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 1792/87714 (1/48, 141 homozygotes, 396 hemizygotes), which significantly exceeds the estimated maxium expected allele frequency for a pathogenic GPC3 variant of 1/10000000. The variant of interest, to our knowledge, has not been reported in affected individuals via publications. A reputable clinical laboratory cites the variant as "benign." Therefore, the variant of interest is classified as Benign. -

Simpson-Golabi-Behmel syndrome type 1 Benign:1
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Oct 12, 2015
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Hereditary cancer-predisposing syndrome Benign:1
Feb 24, 2020
Sema4, Sema4
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:curation

- -

Wilms tumor 1 Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.92
CADD
Benign
2.2
DANN
Benign
0.39
PhyloP100
0.24
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs61754631; hg19: chrX-132670269; API